UNC1062, a new and potent Mer inhibitor

European Journal of Medicinal Chemistry

Volumn 65, Issue , 2013, Pages 83-93

  Liu, Jing ^a   Zhang, Weihe ^a   Stashko, Michael A ^a   DeRyckere, Deborah ^c   Cummings, Christopher T ^c   Hunter, Debra ^b   Yang, Chao ^a,d   Jayakody, Chatura N ^a   Cheng, Nancy ^a   Simpson, Catherine ^a   Norris Drouin, Jacqueline ^a   Sather, Susan ^c   Kireev, Dmitri ^a   Janzen, William P ^a,b   Earp, H Shelton ^b   Graham, Douglas K ^c   Frye, Stephen V ^a,b   Wang, Xiaodong ^a  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Children's Hospital Colorado   (United States)

^d NONE   (United States)

Author keywords

Glioblastoma; Leukemia; Mer inhibitors; Non small cell lung cancer; Pyrazolopyrimidines; Sulfonamides

Indexed keywords

MER KINASE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; UNC1062; UNCLASSIFIED DRUG;

ARTICLE; COLONY FORMATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION;

EID: 84877845714     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.03.035     Document Type: Article

References (33)

1. J. Chen, K. Carey, P.J. Godowski, Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation, Oncogene 14 (17) (1997) 2033-2039.
2. R.M.A. Linger, A.K. Keating, H.S. Earp, D.K. Graham, TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer, in: Advances in Cancer Research, vol. 100, Academic Press, New York, 2008, pp. 35-83.
3. (a) R.M.A. Linger, A.K. Keating, H.S. Earp, D.K. Graham, Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors, Expert Opin. Ther. Targets 14 (10) (2010) 1073-1090;
4. (b) L. Brandao, J. Migdall-Wilson, K. Eisenman, D.K. Graham, TAM receptors in leukemia: expression, signaling, and therapeutic implications, Crit. Rev. Oncog. 16 (1-2) (2011) 47-63.
5. (a) D.K. Graham, D.B. Salzberg, J. Kurtzberg, S. Sather, G.K. Matsushima, A.K. Keating, X. Liang, M.A. Lovell, S.A. Williams, T.L. Dawson, M.J. Schell, A.A. Anwar, H.R. Snodgrass, H.S. Earp, Ectopic expression of the protooncogene Mer in pediatric T-cell acute lymphoblastic leukemia, Clin. Cancer Res. 12 (9) (2006) 2662-2669;
6. (b) E.J. Yeoh, M.E. Ross, S.A. Shurtleff, W.K. Williams, D. Patel, R. Mahfouz, F.G. Behm, S.C. Raimondi, M.V. Relling, A. Patel, C. Cheng, D. Campana, D. Wilkins, X. Zhou, J. Li, H. Liu, C.H. Pui, W.E. Evans, C. Naeve, L. Wong, J.R. Downing, Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling, Cancer Cell 1 (2) (2002) 133-143;
7. (c) L.N. Brandao, A. Winges, S. Christoph, S. Sather, A. McGranahan, X. Liang, D. Gao, D. DeRyckere, D.K. Graham, Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia, Blood Cancer J. 3 (2013) e101, http://dx.doi.org/10.1038/bcj.2012.46.
8. A.B. Lee-Sherick, K.M. Eisenman, S. Sather, A. McGranahan, P.M. Armistead, C.S. McGary, S.A. Hunsucker, J. Schlegel, H. Martinson, C. Cannon, A.K. Keating, H.S. Earp, X. Liang, D. DeRyckere, D.K. Graham, Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia, Oncogene (2013). http://dx.doi.org/10.1038/onc.2013.40.
9. R.M. Linger, R.A. Cohen, C.T. Cummings, S. Sather, J. Migdall-Wilson, D.H. Middleton, X. Lu, A.E. Baron, W.A. Franklin, D.T. Merrick, P. Jedlicka, D. Deryckere, L.E. Heasley, D.K. Graham, Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer, Oncogene (2012). http://dx.doi.org/10.1038/ onc.2012.355.
10. (a) A.K. Keating, G.K. Kim, A.E. Jones, A.M. Donson, K. Ware, J.M. Mulcahy, D.B. Salzberg, N.K. Foreman, X. Liang, A. Thorburn, D.K. Graham, Inhibition of Mer and Axl receptor tyrosine kinases in Astrocytoma cells leads to increased apoptosis and improved chemosensitivity, Mol. Cancer Ther. 9 (5) (2010) 1298-1307;
11. (b) A.E. Rogers, J.P. Le, S. Sather, B.M. Pernu, D.K. Graham, A.M. Pierce, A.K. Keating, Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology, Oncogene 31 (38) (2012) 4171-4181;
12. (c) Y. Wang, G. Moncayo, P. Morin Jr., G. Xue, M. Grzmil, M.M. Lino, V. Clement-Schatlo, S. Frank, A. Merlo, B.A. Hemmings, Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme, Oncogene (2012) 1-11.
13. (a) J. Schlegel, M.J. Sambade, S. Sather, S.J. Moschos, A.-C. Tan, A. Winges, D. DeRyckere, C.C. Carson, D.G. Trembath, J.J. Tentler, S.G. Eckhardt, P.-F. Kuan, R.L. Hamilton, L.M. Duncan, C.R. Miller, N. Nikolaishvili-Feinberg, B.R. Midkiff, J. Liu, W. Zhang, C. Yang, X. Wang, S.V. Frye, H.S. Earp, J.M. Shields, D.K. Graham, MERTK receptor tyrosine kinase is a therapeutic target in melanoma, J. Clin Invest. (2013). http://dx.doi.org/10.1172/JCI67816;
14. (b) K. Tworkoski, G. Singhal, S. Szpakowski, C.I. Zito, A. Bacchiocchi, V. Muthusamy, M. Bosenberg, M. Krauthammer, R. Halaban, D.F. Stern, Phosphoproteomic screen identifies potential therapeutic targets in melanoma, Mol. Cancer Res. 9 (6) (2011) 801-812.
15. A.K. Keating, D.B. Salzberg, S. Sather, X. Liang, S. Nickoloff, A. Anwar, D. Deryckere, K. Hill, D. Joung, K.K. Sawczyn, J. Park, D. Curran-Everett, L. McGavran, L. Meltesen, L. Gore, G.L. Johnson, D.K. Graham, Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase, Oncogene 25 (45) (2006) 6092-6100.
16. (a) X. Huang, P. Finerty Jr., J.R. Walker, C. Butler-Cole, M. Vedadi, M. Schapira, S.A. Parker, B.E. Turk, D.A. Thompson, S. Dhe-Paganon, Structural insights into the inhibited states of the Mer receptor tyrosine kinase, J. Struct. Biol. 165 (2) (2009) 88-96;
17. (b) J. Greshock, K.E. Bachman, Y.Y. Degenhardt, J. Jing, Y.H. Wen, S. Eastman, E. McNeil, C. Moy, R. Wegrzyn, K. Auger, M.A. Hardwicke, R. Wooster, Molecular target class is predictive of in vitro response profi le, Cancer Res. 70 (9) (2010) 3677-3686;
18. (c) S. Howard, V. Berdini, J.A. Boulstridge, M.G. Carr, D.M. Cross, J. Curry, L.A. Devine, T.R. Early, L. Fazal, A.L. Gill, M. Heathcote, S. Maman, J.E. Matthews, R.L. McMenamin, E.F. Navarro, M.A. O'Brien, M. O'Reilly, D.C. Rees, M. Reule, D. Tisi, G. Williams, M. Vinkovic, P.G. Wyatt, Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity, J. Med. Chem. 52 (2) (2009) 379-388;
19. G.M. Schroeder, Y. An, Z.W. Cai, X.T. Chen, C. Clark, L.A. Cornelius, J. Dai, J. Gullo-Brown, A. Gupta, B. Henley, J.T. Hunt, R. Jeyaseelan, A. Kamath, K. Kim, J. Lippy, L.J. Lombardo, V. Manne, S. Oppenheimer, J.S. Sack, R.J. Schmidt, G. Shen, K. Stefanski, J.S. Tokarski, G.L. Trainor, B.S. Wautlet, D. Wei, D.K. Williams, Y. Zhang, J. Fargnoli, R.M. Borzilleri, Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4- fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily, J. Med. Chem. 52 (5) (2009) 1251-1254.
20. J. Liu, C. Yang, C. Simpson, D. DeRyckere, D.A. Van, M.J. Miley, D. Kireev, J. Norris-Drouin, S. Sather, D. Hunter, V.K. Korboukh, H.S. Patel, W.P. Janzen, M. Machius, G.L. Johnson, H.S. Earp, D.K. Graham, S.V. Frye, X. Wang, Discovery of small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia, ACS Med. Chem. Lett. 3 (2012) 129-134.
21. (a) A.E. Dubin, N. Nasser, J. Rohrbacher, A.N. Hermans, R. Marrannes, C. Grantham, K. Van Rossem, M. Cik, S.R. Chaplan, D. Gallacher, J. Xu, A. Guia, N.G. Byrne, C. Mathes, Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp, J. Biomol. Screen. 10 (2) (2005) 168-181;
22. (b) H.J. Witchel, J.T. Milnes, J.S. Mitcheson, J.C. Hancox, Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes, J. Pharmacol. Toxicol. Methods 48 (2) (2002) 65-80.
23. (a) B. Priest, I.M. Bell, M. Garcia, Role of hERG potassium channel assays in drug development, Channels 2 (2) (2008) 87-93;
24. (b) W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, S. Palethorpe, P.K. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm, T.G. Hammond, Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development, Cardiovasc. Res. 58 (1) (2003) 32-45;
25. (c) S. Picard, P. Lacroix, QT interval prolongation and cardiac risk assessment for novel drugs, Curr. Opin. Investig. Drugs 4 (3) (2003) 303-308;
26. F. De Ponti, E. Poluzzi, A. Cavalli, M. Recanatini, N. Montanaro, Safety of nonantiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview, Drug Saf.: Int. J. Med. Toxicol. Drug Experience 25 (4) (2002) 263-286.
27. J. Liu, X. Wang, Microwave-assisted, divergent solution-Phase synthesis of 1,3,6-Trisubstituted pyrazolo[3,4-d]pyrimidines, ACS Comb. Sci. 13 (4) (2011) 414-420.
28. (a) A. Pommereau, E. Pap, A. Kannt, Two simple and generic antibody-independent kinase assays: comparison of a bioluminescent and a microfluidic assay format, J. Biomol. Screen. 9 (5) (2004) 409-416;
29. (b) J. Dunne, H. Reardon, V. Trinh, E. Li, J. Farinas, Comparison of on-chip and off-chip microfluidic kinase assay formats, Assay Drug Dev. Technol. 2 (2) (2004) 121-129;
30. (c) P. Bernasconi, M. Chen, S. Galasinski, I. Popa-Burke, A. Bobasheva, L. Coudurier, S. Birkos, R. Hallam, W.P. Janzen, A chemogenomic analysis of the human proteome: application to enzyme families, J. Biomol. Screen. 12 (7) (2007) 972-982.
31. X. Wang, J. Liu, C. Yang, W. Zhang, S. Frye, D. Kireev, Preparation of Pyrazolopyrimidine Compounds for the Treatment of Cancer. WO2011146313A1 (2011).
32. (a) J.F. Morrison, Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors, Biochim. Biophys. Acta 185 (2) (1969) 269-286;
33. (b) R.A. Copeland, Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists, Methods Biochem. Anal. 46 (2005) 178-189.